azomycin has been researched along with Infarction, Middle Cerebral Artery in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beppu, T; Kobayashi, M; Ogasawara, K; Ogawa, A; Saura, H; Takai, Y; Terasaki, K; Yoshida, K | 1 |
| Aramori, I; Furuichi, Y; Ishiye, M; Matsuoka, N; Mutoh, S; Noto, T; Yanagihara, T | 1 |
2 other study(ies) available for azomycin and Infarction, Middle Cerebral Artery
| Article | Year |
|---|---|
Hypoxic viable tissue in human chronic cerebral ischemia because of unilateral major cerebral artery steno-occlusive disease.
Topics: Adult; Aged; Aged, 80 and over; Arterial Occlusive Diseases; Brain Chemistry; Brain Ischemia; Cerebral Arterial Diseases; Cerebrovascular Circulation; Chronic Disease; Female; Humans; Hypoxia; Infarction, Middle Cerebral Artery; Male; Middle Aged; Nitroimidazoles; Oxygen Consumption; Oxygen Radioisotopes; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals | 2015 |
Tacrolimus (FK506) limits accumulation of granulocytes and platelets and protects against brain damage after transient focal cerebral ischemia in rat.
Topics: Animals; Blood Platelets; Brain Ischemia; Cell Adhesion; Cerebral Cortex; Granulocytes; Infarction, Middle Cerebral Artery; Intercellular Adhesion Molecule-1; Male; Microtubule-Associated Proteins; Neuroprotective Agents; Nitroimidazoles; Rats; Rats, Wistar; Tacrolimus | 2007 |